Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Alter, M.; Volker, B.; Kapp, A.; Gutzmer, R.
Hannover Medical School, Hannover, Germany
We report the case of an 80 year old female patient with surgical non resectable squamous cell carcinoma of the scalp. Although wide surgical resection of the tumour was performed complete resection cold not been reached. Thus subsequent radiotherapy was initiated. 3 months later the patient developed new subcutaneous tumors near the first resection area and at the border of the radiation field. Histopathology showed a recurrence of the squamous cell carcinoma and the patient underwent dose-intensifying radiotherapy. However, the tumor continued to grow within the irradiated area, and additional radiotherapy and surgery were impossible. Staging procedures including cranial and neck computertomography, ultrasound of abdomen and peripheral lymph nodes and chest X-ray showed no evidence for further metastazation. Thus we decided to initiate treatment with the cetuximab, an antibody blocking the epidermal growth factor receptor (EGFR), since successful treatments of advanced squamous cell carcinomas of the skin with EGRF-blockers were reported and cetuximab is licensed for the treatment of head and neck squamous cell cancers. Cetuximab was given as a monotherapy, starting with 400 mg/m2, followed by 250 mg/m2 weekly. Clinically, the tumor rapidly improved. Histopathologically most of the tumor bearing area cleared after 2 months, only in one area a well differentiated cornifying squamous cell carcinoma (instead of the previously undifferentiated squamous cell carcinoma) was seen. Currently, the patient continues cetuximab monotherapy with a mild follicular skin eruption as only side effect. This case report underlines the usefulness of EGFR blockers in the treatment of advanced squamous cell carcinomas of the skin which encourage a clinical study.
© 2010 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at Melanoma Research.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in for
days or until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection